ArticleNPJ precision oncology2024

Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer.

Laura E Johnston et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.